DE69710526D1 - Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen - Google Patents

Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen

Info

Publication number
DE69710526D1
DE69710526D1 DE69710526T DE69710526T DE69710526D1 DE 69710526 D1 DE69710526 D1 DE 69710526D1 DE 69710526 T DE69710526 T DE 69710526T DE 69710526 T DE69710526 T DE 69710526T DE 69710526 D1 DE69710526 D1 DE 69710526D1
Authority
DE
Germany
Prior art keywords
xanomeline
thiadiazol
methylpyridine
hexyloxy
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69710526T
Other languages
English (en)
Other versions
DE69710526T2 (de
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69710526D1 publication Critical patent/DE69710526D1/de
Application granted granted Critical
Publication of DE69710526T2 publication Critical patent/DE69710526T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Medicinal Preparation (AREA)
  • Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Press Drives And Press Lines (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69710526T 1996-08-01 1997-07-25 Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen Expired - Lifetime DE69710526T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2290096P 1996-08-01 1996-08-01

Publications (2)

Publication Number Publication Date
DE69710526D1 true DE69710526D1 (de) 2002-03-28
DE69710526T2 DE69710526T2 (de) 2002-10-02

Family

ID=21812011

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69710526T Expired - Lifetime DE69710526T2 (de) 1996-08-01 1997-07-25 Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen

Country Status (19)

Country Link
EP (1) EP0821955B1 (de)
JP (1) JP2000515547A (de)
KR (1) KR20000029647A (de)
CN (1) CN1226165A (de)
AT (1) ATE213413T1 (de)
AU (1) AU716972B2 (de)
BR (1) BR9710901A (de)
CA (1) CA2261802C (de)
CZ (1) CZ27299A3 (de)
DE (1) DE69710526T2 (de)
DK (1) DK0821955T3 (de)
EA (1) EA199900174A1 (de)
ES (1) ES2171838T3 (de)
HU (1) HUP9904578A2 (de)
IL (1) IL128280A0 (de)
NO (1) NO990436L (de)
PL (1) PL331407A1 (de)
PT (1) PT821955E (de)
WO (1) WO1998005324A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2804215C (en) 2009-07-22 2019-10-01 Eric Elenko Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP2919788A4 (de) 2012-11-14 2016-05-25 Univ Johns Hopkins Verfahren und zusammensetzungen zur behandlung von schizophrenie
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
CN111430027B (zh) * 2020-03-18 2023-04-28 浙江大学 基于肠道微生物的双相情感障碍生物标志物及其筛选应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
EP0734259B1 (de) * 1993-08-19 2002-06-12 Novo Nordisk A/S Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
US5672709A (en) * 1994-10-24 1997-09-30 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
DK0709094T3 (da) * 1994-10-31 2000-07-10 Lilly Co Eli Tetrahydropyridinoxadiazol- eller thiadiazolforbindelse til behandling af angst

Also Published As

Publication number Publication date
CN1226165A (zh) 1999-08-18
IL128280A0 (en) 1999-11-30
KR20000029647A (ko) 2000-05-25
DK0821955T3 (da) 2002-03-18
EP0821955B1 (de) 2002-02-20
AU716972B2 (en) 2000-03-09
JP2000515547A (ja) 2000-11-21
CA2261802A1 (en) 1998-02-12
EP0821955A2 (de) 1998-02-04
ATE213413T1 (de) 2002-03-15
NO990436D0 (no) 1999-01-29
HUP9904578A2 (hu) 2000-06-28
WO1998005324A1 (en) 1998-02-12
DE69710526T2 (de) 2002-10-02
EP0821955A3 (de) 1998-04-22
PT821955E (pt) 2002-07-31
EA199900174A1 (ru) 1999-08-26
NO990436L (no) 1999-01-29
BR9710901A (pt) 1999-08-17
CA2261802C (en) 2006-11-07
CZ27299A3 (cs) 1999-08-11
AU4046897A (en) 1998-02-25
ES2171838T3 (es) 2002-09-16
PL331407A1 (en) 1999-07-19

Similar Documents

Publication Publication Date Title
DE69634733D1 (de) Benzamidoxime prodrugs und verwendung zur behandlung von pneumonie
FI935529A (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
ATE425750T1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
ATE399547T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
ATE231131T1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
ATE156359T1 (de) Phosphatdiester zur behandlung von proliferativen erkrankungen der epidermis
DE69710526D1 (de) Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen
DE3887598D1 (de) Pharmazeutisch verwendbare polymorphe Modifikation von Buspiron.
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
DE69816244D1 (de) Verwendung von 2-Aryl-3-aroylbenzo(b)thiophene zur Behandlung des Oestrogenenthaltungssyndroms
DE69713571D1 (de) Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen
DE59109225D1 (de) Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DE69904849D1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
NO20003481L (no) FremgangsmÕte for behandling av COPD
ATE470671T1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
DE69823650D1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
DE69916577D1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
DE69941134D1 (de) Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN